Antibody-drug Conjugate Report Cover TrendFeedr

Antibody-drug Conjugate Report

: Analysis on the Market, Trends, and Technologies
446
TOTAL COMPANIES
Established
Topic Size
Incremental
ANNUAL GROWTH
Growing
trending indicator
16.7B
TOTAL FUNDING
Maturing
Topic Maturity
Balanced
TREND HYPE
831.0
Monthly Search Volume

The antibody-drug conjugate (ADC) sector is experiencing a transformative phase with a surge in pharmaceutical companies investing in this innovative approach to cancer treatment. ADCs represent a class of biopharmaceutical drugs designed for targeted cancer therapy, aiming to selectively destroy cancer cells while preserving healthy tissues. The data indicates a maturing market with 446 companies actively involved, signifying a solid foundation for growth and innovation. Key trends show a substantial increase in media presence, industry growth, and public interest, with a notable rise in funding and investment from major entities. The ADC landscape is diverse, with companies varying in size, revenue levels, and growth rates, all contributing to an increasingly visible and significant market presence.

Antibody-drug Conjugate Evolution: Last 5 Years Trendline showcasing combined relative share of Antibody-drug Conjugate in industry growth, news coverage, and public interest

Relative share growth in the last 5 years: -9.43%
Growth per month: -0.16%

Key Activities and Applications

  • Development of next-generation multifunctional biotherapeutics.
  • Creation of inteins-based biochemical tools for gene therapy and ADC manufacture.
  • Advancement of therapeutics to expand treatment options for solid tumors.
  • Specialization in immuno-oncology, antibodies, and bispecifics.
  • Provision of one-stop-shop services for biologics development, including CDMO for ADCs.
  • Focus on developing revolutionary therapies for chronic pain, neurological disorders, and cancer.
  • Development of dual kinase inhibitors for cancer treatment.

Technologies and Methodologies

  • Azymetric™ and ALiCE technologies for highly differentiated product candidates.
  • Inteins-based technologies for protein conjugation and purification.
  • Groundbreaking technology for identifying druggable and specific targets in disease treatment.
  • High-density tissue arrays for large-scale analysis of gene/protein expression.

Antibody-drug Conjugate Funding

A total of 207 Antibody-drug Conjugate companies have received funding.
Overall, Antibody-drug Conjugate companies have raised $16.7B.
Companies within the Antibody-drug Conjugate domain have secured capital from 650 funding rounds.

The chart shows the funding trendline of Antibody-drug Conjugate companies over the last 5 years

Funding growth in the last 5 years: 191.51%
Growth per month: 1.86%

Antibody-drug Conjugate Companies

The Companies feature is a crucial part of TrendFeedr. It offers in-depth information about 446 companies working within Antibody-drug Conjugate and other trends and technologies. Identify and analyze innovators and key players in relevant industries more easily with this feature.

companies image

446 Antibody-drug Conjugate Companies

Discover Opportunities with Graphs, Charts, Trend Matrices, and Comparisons

View all Companies

Antibody-drug Conjugate Investors

TrendFeedr’s investors tool offers a detailed view of investment activities that align with specific trends and technologies. This tool features comprehensive data on 262 Antibody-drug Conjugate investors, funding rounds, and investment trends, providing an overview of market dynamics.

investors image

262 Antibody-drug Conjugate Investors

Discover Opportunities with Graphs, Charts, Trend Matrices, and Comparisons

View all Investors

Antibody-drug Conjugate News

Stay informed and ahead of the curve with TrendFeedr’s News feature, which provides access to 2.0K Antibody-drug Conjugate articles. The tool is tailored for professionals seeking to understand the historical trajectory and current momentum of changing market trends.

articles image

2.0K Antibody-drug Conjugate News Articles

Discover Opportunities with Graphs, Charts, Trend Matrices, and Comparisons

View all Articles

Executive Summary

Antibody-drug conjugates are at the forefront of a revolution in cancer therapy. The sector is characterized by a robust and maturing market, with significant advancements and investments driving growth and innovation. Companies are engaged in a range of activities, from the development of multifunctional biotherapeutics to the creation of inteins-based biochemical tools and dual kinase inhibitors. The increasing media presence and funding growth underscore the rising prominence of ADCs in the business landscape. With ongoing research and strategic investments, ADCs are poised to continue their trajectory of transformative impact within the biopharmaceutical domain.

StartUs Insights logo

Discover our Free Healthcare Trends Report

DOWNLOAD
Discover emerging Healthcare Trends!
We'll deliver our free report straight to your inbox!



    Protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

    Spot Emerging Trends Before Others

    Get access to the full database of 20,000 trends



      Protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.




        This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

        Let's talk!



          Protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.